Beacon Biosignals, Inc. — SEC Form D Filing

Beacon Biosignals, Inc. filed an SEC Form D on April 15, 2026, reporting $103.28M raised in Healthcare Technology.

Form D filing details

Filing
SEC Form D
Filing date
April 15, 2026
Amount reported
$103.28M
Round stage
Series B+
Industry
Healthcare Technology
Website
https://beacon.bio/

What the company does

Securities: Equity. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Many patients suffer from neurological and psychiatric conditions without effective treatments due to the complexity of the brain. This gap leads to a lack of answers and adequate care.

Solution

Beacon Biosignals uses AI-driven neurotechnology to provide precise neuroscience insights for clinical trials, enabling faster and more effective drug development for unmet medical needs.

Verdict

Investors said yes because they recognized a pressing need for innovation in treating neurological and psychiatric disorders, not because existing solutions were meeting that demand. They were implicitly betting on the transformative potential of AI in neuroscience, particularly in clinical trial applications. However, the limited upside stems from the over-saturation of AI applications in healthcare, which raises questions about Beacon Biosignals' unique value proposition and long-term market viability.

Source: SEC EDGAR Form D filing